SAVIENT CHAPTER 11 CASE INFORMATION
contact

 


home

KRYSTEXXA® (pegloticase)

 

For additional information, please call the KRYSTEXXA Hotline at:
1-888-KRYSTEXXA (1-888-579-7839)

 

We have exclusively licensed worldwide rights to the technology related to KRYSTEXXA (pegloticase) and its uses from Duke University and Mountain View Pharmaceuticals, Inc. Duke University developed the recombinant uricase enzyme and Mountain View developed the PEGylation technology used in the manufacture of KRYSTEXXA. Mountain View and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.

This site is intended for U.S. audiences only.

 

     
     
 
For Chapter 11 Case Information relating to Savient Pharmaceuticals, Inc. and Savient Pharma Holdings, Inc Click Here